SPIKEVAX is now updated for 2024 Fall Season.
COVID-19 has evolved. Our updated KP.2 mRNA vaccine is available.1,2
One size fits all*
One simple vial presentation, for all individuals 6 months of age and older.
New season. New shot.
The SPIKEVAX (COVID-19 mRNA vaccine) Formulation has been updated to protect against COVID-19.
NACI strongly recommends COVID-19 vaccination is for previously vaccinated and unvaccinated individuals at increased risk of SARS-CoV-2 infection or severe COVID-19 disease as follows:
- All adults 65 years of age or older
- Those 6 months of age and older who are:
- Residents of long-term care homes and other congregate living settings
- Individuals with underlying medical conditions that place them at higher risk of severe COVID-19, including children** with complex health needs
- Individuals who are pregnant
- Individuals in or from First Nations, Métis and Inuit communities‡
- Members of racialized and other equity-deserving communities
- People who provide essential community services
According to NACI, All other previously vaccinated and unvaccinated individuals (6 months of age and older) who are not at increased risk for SARS-CoV-2 infection or severe COVID-19 disease (i.e., not on the list above) may receive the most recently updated vaccine in the fall of 2024.
For unvaccinated individuals 5 years of age and older who are moderately to severely immunocompromised, NACI recommends that 2 doses should be given (Strong NACI recommendation) and an additional dose (for a total of 3 doses) may be given, regardless of vaccine platform.
Underlying medical conditions associated with more severe COVID-19 disease
- Cancer
- Cerebrovascular disease
- Chronic kidney disease
- Chronic liver diseases (limited to: cirrhosis, non-alcoholic fatty liver disease, alcoholic liver disease, and autoimmune hepatitis)
- Chronic lung diseases (limited to: bronchiectasis, chronic obstructive pulmonary disease, interstitial lung disease, pulmonary hypertension, pulmonary embolism)
- Cystic fibrosis
- Diabetes mellitus, type 1 and type 2
- Disabilities (e.g. Down syndrome, learning, intellectual, or developmental disabilities; ADHD; cerebral palsy; congenital disabilities; spinal cord injuries)
- Heart conditions (e.g., cardiomyopathies, coronary artery disease, heart failure, etc.)
- HIV infection
- Mental health disorders (limited to: mood disorders, including depression; schizophrenia spectrum disorders)
- Obesity
- Pregnancy and recent pregnancy
- Primary immunodeficiency diseases
- Smoking, current or former
- Solid organ or blood stem cell transplant
- Tuberculosis
- Use of corticosteroids or other immunosuppressive medication
We're here to help
Get in touch with questions or for any information you may need.
One size fits all.
Download to view the full Dosing Administration Storage and Handling Document for healthcare providers.
SPIKEVAX (COVID-19 mRNA vaccine) is indicated for active immunization against coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in individuals 6 months of age and older.
Pediatrics: Safety and efficacy in individuals <6 months of age not established.
Contraindications:
- Hypersensitivity to the active ingredient or to any ingredients in the formulation, including any non-medicinal ingredient, or component of the container.
Relevant warnings and precautions:
- Hypersensitivity and anaphylaxis
- Myocarditis and pericarditis
- Patients with acute infection
- Patients with hematologic disorders or on anticoagulant therapy
- Patients who are immunocompromised
- Syncope
- Vaccination with SPIKEVAX may not protect all recipients
For more information:
Please consult the Product Monograph at spikevaxpro.com/pm for important information relating to adverse reactions, drug interactions, and dosing information which has not been discussed in this piece. The Product Monograph is also available by calling us at 1-866-MODERNA (1-866-663-3762).
Footnotes
* SPIKEVAX (COVID-19 mRNA vaccine) is indicated for Active immunization against coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in individuals 6 months of age and older.
**There is limited evidence on clinical risk factors for severe COVID-19 disease in pediatric populations. Children at increased risk for severe outcomes may include children who are medically fragile/have medical complexities, children with more than one comorbidity, children with neurological disorders, children with chronic lung disease, and children with Down syndrome (Trisomy 21), and other immunocompromising conditions.
‡Autonomous decisions should be made by Indigenous Peoples with the support of healthcare and public health partners in accordance with the United Nations Declaration on the Rights of Indigenous Peoples Act.
Stay up to date
Receive the latest information about all the products in the Moderna pipeline.
By submitting your information, you agree to Moderna's Terms and Conditions. You also acknowledge that your information will be processed in accordance with Moderna's Privacy Statement. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
© 2024 ModernaTX, Inc. CA-COV-2300031 09/2024